Syntimmune

Syntimmune

Syntimmune

Founded in 2013, Syntimmune is the worlds leader in the biology of the neonatal Fc receptor (FcRn). Syntimmune's lead program targets FcRn.
Founded
2013
Raised
$84M
Follow us
Alexa global traffic share
Latest funding Show all
Team Size
1–10
Employees
FinSMEs

Alexion To Acquire Syntimmune, for Up To $1.2 Billion

Health
PE HUB

| Apple Tree-backed Syntimmune appoints president and CEO

Strategy Health
Xconomy

Syntimmune Snares $50M to Test Autoimmune Drug in Two Rare Diseases

Health Science
$26,000,000 Venture capital (Series A)
VentureWire

The Daily Startup: Syntimmune Fights Autoimmune Diseases With New Funds

Funding
$26,000,000 Venture capital (Series A)
businesswire

Syntimmune Secures Second Tranche of $26 Million Series A Financing

Xconomy

NY Bio Startup Syntimmune Gets $10M From Baxalta, Apple Tree

Funding Health